Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests

doi: 10.1093/cid/cix672

Figure Lengend Snippet: Results of Enzyme-Linked Immunosorbent Assays in Different Serum/Plasma Panels

Article Snippet: Purified DENV1-NS1 protein was purchased from the Native Antigen (United Kingdom).

Techniques:

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests

doi: 10.1093/cid/cix672

Figure Lengend Snippet: Sensitivity and Specificity of Enzyme-Linked Immunosorbent Assays

Article Snippet: Purified DENV1-NS1 protein was purchased from the Native Antigen (United Kingdom).

Techniques:

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests

doi: 10.1093/cid/cix672

Figure Lengend Snippet: Results of nonstructural protein 1 (NS1) immunoglobulin G (IgG) enzyme-linked immunosorbent assays (ELISAs) for secondary dengue virus (sDENV) and Zika virus (ZIKV) with previous (wp) DENV infection panels. DENV1-NS1 (A) and ZIKV-NS1 (B) IgG ELISAs in convalescent-phase samples from sDENV, ZIKVwpDENV (Nicaragua [Nic]), probable ZIKVwpDENV (Brazil [Bra]) and negative control (NC) panels. C, Relative optical density (rOD) ratio of ZIKV-NS1 to DENV1-NS1. The sensitivity and specificity are shown based on a cutoff rOD ratio at 0.24. DENV1-NS1 (D) and ZIKV-NS1 (E) IgG ELISAs in post–convalescent phase samples (3 months to 2 years post–symptom onset) from sDENV panels. F, Positive rates of DENV1- and ZIKV-NS1 IgG ELISAs in sDENV panels over time. Dotted lines indicate cutoff rOD values for ELISAs. Data are mean of 2 experiments (each in duplicate). Two-tailed Mann-Whitney test was used to compare the 2 groups.

Article Snippet: Purified DENV1-NS1 protein was purchased from the Native Antigen (United Kingdom).

Techniques: Virus, Infection, Negative Control, Two Tailed Test, MANN-WHITNEY

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests

doi: 10.1093/cid/cix672

Figure Lengend Snippet: Results of nonstructural protein 1 (NS1) immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISAs) in sequential samples from individuals with secondary dengue virus (sDENV) and Zika virus (ZIKV) infection with previous (wp) DENV infections. A, Three cases with sDENV infection, 3–18 months post–symptom onset. B, Four blood donors with sDENV infection, 7 days to 6 months post–index day (PID). C, Five blood donors with ZIKVwpDENV infection, from index day to 3 months PID. Three cases (1, 4, and 7) seroconverted to ZIKV-NS1; 2 cases (15 and 21) had ZIKV-NS1 IgG starting from the index day. Dotted lines indicate cutoff relative optical density (rOD) values for ELISAs. Data are mean of 2 experiments (each in duplicates).

Article Snippet: Purified DENV1-NS1 protein was purchased from the Native Antigen (United Kingdom).

Techniques: Enzyme-linked Immunosorbent Assay, Virus, Infection

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests

doi: 10.1093/cid/cix672

Figure Lengend Snippet: Proposed algorithm of using 3 serological tests (without neutralization tests) to distinguish different Zika virus (ZIKV) and dengue virus (DENV) infections in dengue- and Zika-endemic regions in the framework of Centers for Disease Control and Prevention guidelines for laboratory diagnosis of ZIKV infection [6, 7]. Only samples tested positive or equivocal by ZIKV or DENV E protein–based immunoglobulin M (IgM) enzyme-linked immunosorbent assays (ELISAs) are included in the algorithm. The total numbers from each panel and the numbers of positive or negative based on the 3 Nonstructural Protein 1 (NS1) ELISAs are shown in parentheses. Abbreviations: IgG, immunoglobulin G; OD, optical density; pDENV, primary dengue virus infection; pZIKV, primary Zika virus infection; rOD, relative OD; sDENV, secondary dengue virus infection; ZIKVwpDENV, Zika virus infection with previous dengue virus infection.

Article Snippet: Purified DENV1-NS1 protein was purchased from the Native Antigen (United Kingdom).

Techniques: Neutralization, Virus, Infection

Journal: PLoS Pathogens

Article Title: Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue

doi: 10.1371/journal.ppat.1007500

Figure Lengend Snippet: Clinical characteristics cohorts Bandung and Jepara.

Article Snippet: Washed platelets (1x10 7 plt/ml) were exposed to different concentrations (1.25–10 μg/ml) of NS1 protein from dengue virus serotype 2 (DENV2, strain Thailand/16681/84) (Native Antigen, Oxfordshire, United Kingdom) and incubated for 4 hours at 37°C.

Techniques:

Journal: PLoS Pathogens

Article Title: Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue

doi: 10.1371/journal.ppat.1007500

Figure Lengend Snippet: Binding of (A) SNA or (B) MAL-II lectins to washed platelets or (C) the expression of P-selectin after incubation with two concentrations of DENV2 NS1 protein for 4 hrs at 37°C (n = 7 platelet donors). (D) shows expression of platelet P-selectin and (E-G) the binding of SNA, MAL-II, or RCA lectins to washed platelets following incubation with dengue virus type 2 (DENV 2) for 3 hrs at 37°C (n = 8 platelet donors). Purified neuraminidase from C . perfringens (100 mU) and the platelet agonist adenosine diphosphate (ADP) at 125 μM were used as positive controls. Mock infection with supernatant of uninfected C6/36 cells harvested at the same time as DENV2 stocks was used as negative control. Data are shown as geometric mean with 95% confidence interval. Samples depicted in panels A-C were analyzed on a Beckman coulter Cytoflex, and samples in panel D-G on a FC500 flow cytometer, which explains the differences in MFI values. Differences between groups were analyzed using the Mann-Whitney U test, * P < 0.05, ** P <0.01, *** P <0.001.

Article Snippet: Washed platelets (1x10 7 plt/ml) were exposed to different concentrations (1.25–10 μg/ml) of NS1 protein from dengue virus serotype 2 (DENV2, strain Thailand/16681/84) (Native Antigen, Oxfordshire, United Kingdom) and incubated for 4 hours at 37°C.

Techniques: Binding Assay, Expressing, Incubation, Virus, Purification, Infection, Negative Control, Flow Cytometry, MANN-WHITNEY

Journal: Expert review of vaccines

Article Title: Dengue vaccines: recent developments, ongoing challenges and current candidates

doi: 10.1586/14760584.2013.815412

Figure Lengend Snippet: Dengue virus vaccine candidates in clinical trials. Clinical trials to evaluate DENV vaccine candidates registered on ClinicalTrials.gov are shown. We have not listed earlier studies that do not have a ClinicalTrials.gov identifier. Primary completion dates for the studies shown range from 2005-present. The primary completion/estimated primary completion date refers to the final data collection date for the primary outcome measure and is listed as provided by ClinicalTrials.gov . The enrollment is also that provided by ClinicalTrials.gov .

Article Snippet: Walter Reed Army Institute of Research (WRAIR) and GlaxoSmithKline (GSK) TDV A TDV prepared from four monovalent DENV vaccines (DENV1–4) attenuated by serial passage in primary dog kidney (PDK) cells was tested in infants, children, and adults in Phase 1 and 2 clinical trials ( ) [ 105 – 107 , 115 ].

Techniques: Activity Assay, Injection, Purification

Journal: Journal of Clinical Microbiology

Article Title: Excellent capability for molecular detection of Aedes -borne dengue, Zika, and chikungunya viruses but with a need for increased capacity for yellow fever and Japanese encephalitis viruses: an external quality assessment in 36 European laboratories

doi: 10.1128/jcm.00910-24

Figure Lengend Snippet: Final diagnostic outcome reported by all laboratories ^a

Article Snippet: Clonit SRL DENV1–4 , 1 , False positive ( n = 1).

Techniques: Diagnostic Assay

Journal: Journal of Clinical Microbiology

Article Title: Excellent capability for molecular detection of Aedes -borne dengue, Zika, and chikungunya viruses but with a need for increased capacity for yellow fever and Japanese encephalitis viruses: an external quality assessment in 36 European laboratories

doi: 10.1128/jcm.00910-24

Figure Lengend Snippet: Overview of self-reported diagnostic assays used by 36 laboratories that participated in the EQA for arboviruses ^a

Article Snippet: Clonit SRL DENV1–4 , 1 , False positive ( n = 1).

Techniques: Diagnostic Assay, Multiplex Assay, Virus, Sequencing, Next-Generation Sequencing